Area of research
Hepatology · Epidemiology
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Liver Disease Diagnosis and Treatment, Cholangiocarcinoma and Gallbladder Cancer Studies, and Liver Disease and Transplantation.
BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial.
Association of Epigenetic Aging Biomarkers With Risk of MASLD-Related HCC.
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study
Optimizing Liver Cancer Care Through BCLC Principles.
Correction: Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stages.
Reproducibility and accuracy of non-contrast abbreviated magnetic resonance imaging of the liver in surveillance for early recurrence for hepatocellular carcinoma in a Western population: a multi-reader study.
Immune remodeling via mitochondria-dependent STING activation enhances cabozantinib response in hepatocellular carcinoma.
Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy.
Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).
Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort.
ATF4 programs proline-dependent immune evasion in β-Catenin-driven hepatocellular carcinoma
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma.
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC
BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death.
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial
Evolving epidemiology of HCC in Spain.
Diagnostic performance of contrast-enhanced US in small liver nodules not conclusively characterized after MRI in cirrhotic patients.
Genome-Wide DNA Methylation Markers Associated With Metabolic Liver Cancer.
Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes.
Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on Immunotherapy.
Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stages.
Hepatocellular carcinoma with macrovascular invasion: Review and survival meta-analysis of initial local therapy using minimal prognostic criteria.
Erratum to: Defining Minimum Treatment Parameters of Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma: An Expert Consensus. Yanagihara TK, Tepper JE, Moon AM, et al. Pract Radiat Oncol. 2024 Mar-Apr;14(2):134-145.
Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
A three-gene resistome signature as a prognostic tool in hepatocellular carcinoma.